Copyright Reports & Markets. All rights reserved.

Global HER-2 Targeted Drugs for Breast Cancer Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Trastuzumab
      • 1.4.3 Pertuzumab
      • 1.4.4 Lapatinib
      • 1.4.5 Neratinib
      • 1.4.6 Trastuzumab Emtansine
      • 1.4.7 Pyrotinib
      • 1.4.8 Other
    • 1.5 Market by Application
      • 1.5.1 Global HER-2 Targeted Drugs for Breast Cancer Market Share by Application (2014-2025)
      • 1.5.2 Hospital
      • 1.5.3 Clinic
      • 1.5.4 Drug Center
      • 1.5.5 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 HER-2 Targeted Drugs for Breast Cancer Market Size
    • 2.2 HER-2 Targeted Drugs for Breast Cancer Growth Trends by Regions
      • 2.2.1 HER-2 Targeted Drugs for Breast Cancer Market Size by Regions (2014-2025)
      • 2.2.2 HER-2 Targeted Drugs for Breast Cancer Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 HER-2 Targeted Drugs for Breast Cancer Market Size by by Players
      • 3.1.1 Global HER-2 Targeted Drugs for Breast Cancer Revenue by by Players (2014-2019)
      • 3.1.2 Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global HER-2 Targeted Drugs for Breast Cancer Market Concentration Ratio (CR5 and HHI)
    • 3.2 HER-2 Targeted Drugs for Breast Cancer Key Players Head office and Area Served
    • 3.3 Key Players HER-2 Targeted Drugs for Breast Cancer Product/Solution/Service
    • 3.4 Date of Enter into HER-2 Targeted Drugs for Breast Cancer Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2014-2019)
    • 4.2 Global HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States HER-2 Targeted Drugs for Breast Cancer Market Size (2014-2019)
    • 5.2 HER-2 Targeted Drugs for Breast Cancer Key Players in United States
    • 5.3 United States HER-2 Targeted Drugs for Breast Cancer Market Size by Type
    • 5.4 United States HER-2 Targeted Drugs for Breast Cancer Market Size by Application

    6 Europe

    • 6.1 Europe HER-2 Targeted Drugs for Breast Cancer Market Size (2014-2019)
    • 6.2 HER-2 Targeted Drugs for Breast Cancer Key Players in Europe
    • 6.3 Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Type
    • 6.4 Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Application

    7 China

    • 7.1 China HER-2 Targeted Drugs for Breast Cancer Market Size (2014-2019)
    • 7.2 HER-2 Targeted Drugs for Breast Cancer Key Players in China
    • 7.3 China HER-2 Targeted Drugs for Breast Cancer Market Size by Type
    • 7.4 China HER-2 Targeted Drugs for Breast Cancer Market Size by Application

    8 Japan

    • 8.1 Japan HER-2 Targeted Drugs for Breast Cancer Market Size (2014-2019)
    • 8.2 HER-2 Targeted Drugs for Breast Cancer Key Players in Japan
    • 8.3 Japan HER-2 Targeted Drugs for Breast Cancer Market Size by Type
    • 8.4 Japan HER-2 Targeted Drugs for Breast Cancer Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia HER-2 Targeted Drugs for Breast Cancer Market Size (2014-2019)
    • 9.2 HER-2 Targeted Drugs for Breast Cancer Key Players in Southeast Asia
    • 9.3 Southeast Asia HER-2 Targeted Drugs for Breast Cancer Market Size by Type
    • 9.4 Southeast Asia HER-2 Targeted Drugs for Breast Cancer Market Size by Application

    10 India

    • 10.1 India HER-2 Targeted Drugs for Breast Cancer Market Size (2014-2019)
    • 10.2 HER-2 Targeted Drugs for Breast Cancer Key Players in India
    • 10.3 India HER-2 Targeted Drugs for Breast Cancer Market Size by Type
    • 10.4 India HER-2 Targeted Drugs for Breast Cancer Market Size by Application

    11 Central & South America

    • 11.1 Central & South America HER-2 Targeted Drugs for Breast Cancer Market Size (2014-2019)
    • 11.2 HER-2 Targeted Drugs for Breast Cancer Key Players in Central & South America
    • 11.3 Central & South America HER-2 Targeted Drugs for Breast Cancer Market Size by Type
    • 11.4 Central & South America HER-2 Targeted Drugs for Breast Cancer Market Size by Application

    12 International Players Profiles

    • 12.1 Roche
      • 12.1.1 Roche Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 HER-2 Targeted Drugs for Breast Cancer Introduction
      • 12.1.4 Roche Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2014-2019)
      • 12.1.5 Roche Recent Development
    • 12.2 Chugai Pharmaceutical
      • 12.2.1 Chugai Pharmaceutical Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 HER-2 Targeted Drugs for Breast Cancer Introduction
      • 12.2.4 Chugai Pharmaceutical Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2014-2019)
      • 12.2.5 Chugai Pharmaceutical Recent Development
    • 12.3 GlaxoSmithKline
      • 12.3.1 GlaxoSmithKline Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 HER-2 Targeted Drugs for Breast Cancer Introduction
      • 12.3.4 GlaxoSmithKline Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2014-2019)
      • 12.3.5 GlaxoSmithKline Recent Development
    • 12.4 Novartis
      • 12.4.1 Novartis Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 HER-2 Targeted Drugs for Breast Cancer Introduction
      • 12.4.4 Novartis Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2014-2019)
      • 12.4.5 Novartis Recent Development
    • 12.5 Pfizer
      • 12.5.1 Pfizer Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 HER-2 Targeted Drugs for Breast Cancer Introduction
      • 12.5.4 Pfizer Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2014-2019)
      • 12.5.5 Pfizer Recent Development
    • 12.6 CANbridge
      • 12.6.1 CANbridge Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 HER-2 Targeted Drugs for Breast Cancer Introduction
      • 12.6.4 CANbridge Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2014-2019)
      • 12.6.5 CANbridge Recent Development
    • 12.7 Puma Biotechnology
      • 12.7.1 Puma Biotechnology Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 HER-2 Targeted Drugs for Breast Cancer Introduction
      • 12.7.4 Puma Biotechnology Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2014-2019)
      • 12.7.5 Puma Biotechnology Recent Development
    • 12.8 Hengrui Medicine
      • 12.8.1 Hengrui Medicine Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 HER-2 Targeted Drugs for Breast Cancer Introduction
      • 12.8.4 Hengrui Medicine Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2014-2019)
      • 12.8.5 Hengrui Medicine Recent Development
    • 12.9 Beacon Pharmaceuticals Limited
      • 12.9.1 Beacon Pharmaceuticals Limited Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 HER-2 Targeted Drugs for Breast Cancer Introduction
      • 12.9.4 Beacon Pharmaceuticals Limited Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2014-2019)
      • 12.9.5 Beacon Pharmaceuticals Limited Recent Development
    • 12.10 Hetero Drugs
      • 12.10.1 Hetero Drugs Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 HER-2 Targeted Drugs for Breast Cancer Introduction
      • 12.10.4 Hetero Drugs Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2014-2019)
      • 12.10.5 Hetero Drugs Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      In 2018, the global HER-2 Targeted Drugs for Breast Cancer market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global HER-2 Targeted Drugs for Breast Cancer status, future forecast, growth opportunity, key market and key players. The study objectives are to present the HER-2 Targeted Drugs for Breast Cancer development in United States, Europe and China.

      The key players covered in this study
      Roche
      Chugai Pharmaceutical
      GlaxoSmithKline
      Novartis
      Pfizer
      CANbridge
      Puma Biotechnology
      Hengrui Medicine
      Beacon Pharmaceuticals Limited
      Hetero Drugs 

      Market segment by Type, the product can be split into
      Trastuzumab
      Pertuzumab
      Lapatinib
      Neratinib
      Trastuzumab Emtansine
      Pyrotinib
      Other

      Market segment by Application, split into
      Hospital
      Clinic
      Drug Center
      Other

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global HER-2 Targeted Drugs for Breast Cancer status, future forecast, growth opportunity, key market and key players.
      To present the HER-2 Targeted Drugs for Breast Cancer development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of HER-2 Targeted Drugs for Breast Cancer are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now